Biotechnology

INDIANAPOLIS — Verséa Ophthalmics recently has introduced several new technologies for eye care, including the Biovance 3L Ocular amniotic membrane allograft and the T-POC quantitative testing platform for ocular surface disease.

A biotechnology company has announced a partnership with a precision biomedicine firm to advance the use of electroencephalogram biomarkers across its clinical pipeline in neuropsychiatry and cognition.

Ryne Biotechnology Inc. has announced a $4 million Clinical Stage Research Program grant from the California Institute for Regenerative Medicine to advance its lead candidate for the treatment of Parkinson’s disease.

Andrews Medicine and Celltex Therapeutics Corporation have announced the formation of Andrews Celltex Biologics, a new company focused on the development of biotechnology and stem cell research for the treatment of athletic injuries.

Italian-based biotech firm Stevanato Group and Bexson Biomedical Inc. announced a collaboration to treat a wide range of mental health issues with a subcutaneous drug-delivery device, including treatment-resistant depression and PTSD.

Clinical-stage biotech developer ABL Bio Inc. announced it will collaborate and enter a worldwide license agreement with Sanofi to develop and commercialize a treatment for Parkinson’s disease and other potential indications.

Unity Biotechnology will restructure to focus on ophthalmology and neurology pursuits, according to a press release.

Adverum Biotechnologies reported a second quarter net loss of $15 million, or $0.23 per share, compared with a net loss of $18.8 million, or $0.30 per share, at the same time last year, according to a press release.

In this episode, host Shikha Jain, MD, speaks with Brian Fiske about bringing biotech business ideas to fruition, antibody drug conjugate developments and more.